Welcome to our dedicated page for Verona Pharma SEC filings (Ticker: VRNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to historical U.S. Securities and Exchange Commission (SEC) filings for Verona Pharma plc, which previously traded on the Nasdaq Global Market under the ticker VRNA. Verona Pharma was a biopharmaceutical company focused on chronic respiratory diseases, with its lead product Ohtuvayre (ensifentrine) for the maintenance treatment of COPD in adult patients. Its SEC filings document both its development and commercialization activities and the corporate steps that resulted in its acquisition by Merck.
Among the most important filings for VRNA are its Current Reports on Form 8-K. These include detailed descriptions of the July 2025 transaction agreement under which Merck Sharp & Dohme LLC, through a wholly owned subsidiary, agreed to acquire Verona Pharma by means of a court-sanctioned English law scheme of arrangement. Subsequent 8-K filings report shareholder voting results approving the transaction, amendments to Verona’s change-in-control severance plan, and the completion of the acquisition on October 7, 2025, when Merck’s acquisition vehicle obtained all issued and outstanding Verona shares and Verona became an indirect wholly owned subsidiary of Merck.
For trading status and listing history, users can review the Form 25 (Form 25-NSE) filed in connection with the delisting of Verona Pharma’s American Depositary Shares from the Nasdaq Stock Market LLC. The Form 25 identifies Verona Pharma as the issuer and serves as the official notification of removal from listing and/or registration under Section 12(b) of the Exchange Act. Related 8-K disclosures explain Verona’s request for suspension of trading in its ADSs, the plan to file a Form 15 to terminate registration of its shares and ADSs, and the resulting suspension of its reporting obligations under Sections 13(a) and 15(d).
Earlier 8-K filings also describe governance and compensation matters linked to the transaction, such as the voting agreement with certain directors and executive officers to support the scheme of arrangement and changes to the company’s severance plan in the context of a change in control. Together, these filings offer a regulatory record of how Verona Pharma moved from being an independent Nasdaq-listed issuer to a wholly owned subsidiary within Merck’s corporate structure.
On Stock Titan, these VRNA filings are updated from the SEC’s EDGAR system and can be paired with AI-generated summaries that explain the purpose and key points of each document in plain language. Users can quickly understand what a particular 8-K, Form 25 or future Form 15 means for Verona Pharma’s historical shareholders, how the cash consideration per share and per ADS was structured, and how the delisting and deregistration process unfolded. This makes it easier to interpret Verona Pharma’s regulatory history and the implications of its transition off the public markets.
Verona Pharma plc (VRNA) has signed a definitive Transaction Agreement with Merck Sharp & Dohme LLC and its subsidiary Vol Holdings LLC whereby Merck, through Bidco, will acquire 100% of Verona via an English court-sanctioned Scheme of Arrangement.
- Consideration: $13.375 in cash for each ordinary share (nominal £0.05); each American Depositary Share represents eight ordinary shares and will receive $107.00 in cash.
- Equity awards: All outstanding unvested options and time-based RSUs vest immediately before closing; in-the-money options and vested awards convert to a cash payment based on the $107 ADS price, while out-of-the-money options are cancelled.
- Conditions: Verona shareholder approval, sanction by the High Court of Justice of England & Wales, required regulatory clearances and other customary closing conditions.
- Termination provisions: Either party may walk away if the deal is not completed by 8 Jan 2026 (with up to two automatic three-month extensions for pending regulatory approvals). Verona may owe Merck a $100 million termination fee upon specified events such as Board recommendation change or acceptance of a superior proposal.
- Governance safeguards: Verona’s Board unanimously recommends the scheme; directors and certain executives have entered into a Voting Agreement to support the transaction.
- Non-solicitation: Verona is restricted from soliciting competing bids but may engage on a bona fide proposal deemed likely superior, subject to notification and other requirements.
A joint press release (Exhibit 99.1) announcing the agreement was issued on 9 Jul 2025. A proxy statement on Schedule 14A will be filed with the SEC, providing full details for shareholders.
Investor takeaway: The all-cash offer provides immediate liquidity at a fixed price and is backed by a major pharmaceutical acquirer, but completion risk remains until court, shareholder and regulatory approvals are secured.
Merck (NYSE: MRK) has entered a definitive agreement to acquire Verona Pharma plc (Nasdaq: VRNA) for $107 per American Depository Share (each equal to eight ordinary shares) in an all-cash deal valued at approximately $10 billion. The transaction, unanimously approved by both companies’ boards and structured as a UK scheme of arrangement, will add Ohtuvayre (ensifentrine)--the first novel inhaled COPD maintenance therapy in more than 20 years--to Merck’s expanding cardio-pulmonary pipeline.
Ohtuvayre received U.S. FDA approval in June 2024 and has shown rapid uptake since its August 2024 launch, offering combined bronchodilator and non-steroidal anti-inflammatory effects. Closing is targeted for Q4 2025, subject to Hart-Scott-Rodino review, Verona shareholder approval and sanction by the High Court of Justice of England & Wales. Merck will capitalize most of the purchase price as an intangible asset and amortize it as a GAAP-only charge over the product’s life, limiting cash-flow impact.
Citi and Morgan Stanley advised Merck, while Centerview Partners advised Verona. Merck will host an investor call at 8 a.m. ET on 9 July 2025 to discuss the deal and its expected contribution to near- and long-term growth.
Verona Pharma plc (VRNA) filed an amended Form 4 (Form 4/A) disclosing updated insider activity by Andrew Fisher, the company’s General Counsel. On 15 May 2025 Mr. Fisher exercised stock options (transaction code “M”) for 80,000 Ordinary Shares at an exercise price of $2.0113 per share. The filing corrects a typographical error in the price reported in the original Form 4 filed on 16 May 2025.
After the option exercise, Mr. Fisher directly owns 439,999 Ordinary Shares and still holds 2,320,000 options (convertible into Ordinary Shares) with an expiration date of 31 March 2034. The options vested 25% on 4 Mar 2025, with the remainder vesting in 36 equal monthly installments.
Each Ordinary Share is represented by an American Depositary Share (ADS) at a ratio of 8:1. No sales were reported; the transaction increased the reporting person’s equity stake. The amendment solely addresses the previously misstated option price and does not alter the number of shares or options held.